Vaccination with sipuleucel-T produced IgG antibodies to secondary prostatic carcinoma antigens and prolonged survival in some patients, and assaying for antibodies may provide prognostic information and identify new vaccine targets.
In this issue of Clinical Cancer Research, GuaThakurta and colleagues (1) demonstrate
IgG antibodies to non-targeted tumor antigens in some prostatic carcinoma patients who were vaccinated with sipuleucel-T and showed that the antibodies were associated with improved clinical outcome. Although the clinical efficacy of this treatment was modest, much is being learned from the first human therapeutic cancer vaccine that will lead to more efficacious such vaccines.
After many years of controversy, oncoimmunology is approaching the front-line for cancer therapy. Coley reported over 100 years ago that injection of bacterial toxins into advanced cancers induced a therapeutic response in 40 % of cases including the rejection of tumors that were not injected, and Paul Ehrlich speculated over immunological bullets for tumor destruction. Some 50 years later Prehn and others demonstrated that mice immunized against a chemically induced syngeneic tumor rejected transplanted cells from the same tumor, and that the rejection response was primarily mediated by immune lymphocytes. Other studies showed that lymphoid cells in peripheral blood from human cancer patients could recognize and kill the patients' cultured tumor cells also when the patients had advanced disease, and mechanisms which could inhibit this response began to be identified (2) . However, controversy prevailed for many years and many argued that spontaneous tumors, including those in humans, cannot be recognized as foreign by the host's immune system and gave "reasons" why therapeutic vaccines cannot work.
The controversies subsided as more refined techniques were developed. Targets Additional costimulatory receptors (e.g., CD137, OX40) and ligands (e.g., CD137L)
were soon identified as were receptors (e.g., CTLA4, PD-1) and ligands (PDL-1, PDL-2) which could inhibit the generation of an immune response. Importantly, manipulation of the immune response by administering monoclonal antibodies (mAbs) to some of these molecules was found to have strong anti-tumor activity in several preclinical models (6) (7) (8) including the complete regression and cure of large mouse tumors (9) . The discovery of toll-like receptors and their ligands as regulators of innate immune responses provided other approaches to induce a strong anti-tumor response (10) . Another important contribution was the demonstration that the tumor microenvironment is highly immunosuppressive and provides an obstacle to therapeutic tumor vaccination.
Cancer cells have a high mutation rate, variants which lack a particular target are common, and selection for therapy resistance is a major concern for the use of anti- 
provides stronger evidence than any previous study that antigen spreading, detected as IgG antibodies to secondary tumor antigens, can be induced in some of the patients vaccinated against sipuleucel-T (Fig. 1) . Antigen spreading is important since it can dramatically increase the population of lymphoid cells that are engaged in the anti-tumor response. It is noteworthy that those patients where antigen spreading was most pronounced also had the best overall survival. Methods to effectively increase antigen spreading may improve the efficacy of tumor vaccination. As pointed out by GuhaThakurta and colleagues (1), it may also be rewarding to identify those antigens that most effectively induce an antibody response since they may be good for use as primary target antigens to vaccinate against.
